Serina Therapeutics’ President and CEO interviewed by Life Science Leader magazine and Serina is highlighted as “Company to Watch” in 2013

Huntsville, AL, December 18, 2012

Serina Therapeutics, Inc., a pharmaceutical research and development company that is developing a proprietary, patented polymer technology for drug development, announced today that President and CEO Randall W. Moreadith, MD, PhD was interviewed by Life Science Leader magazine. Serina Therapeutics was highlighted in the current issue of Life Science Leader Magazine as a “Company to Watch”.

“It is a privilege to be selected as one of the up and coming companies to watch,” stated Dr. Moreadith. “Our polymer technology represents a new generation in polymer approaches to developing drug conjugates for unmet medical needs.”

Serina Therapeutics is advancing its lead clinical candidate, SER-214, through IND-enabling studies now, and plans to meet with the FDA in the second half of 2013 to discuss its development program for patients with dopamine-responsive disorders. SER-214 is a polyoxazoline (POZ) conjugate of rotigotine, a potent and selective dopamine agonist that can be used in patients with Parkinson’s disease, restless leg syndrome and levo-dopa induced dyskinesias. The drug candidate SER-214 can be administered as a single, weekly subcutaneous injection in these patients. The rotigotine attached to the polymer is slowly released over a period of approximately one week and provides continuous dopaminergic stimulation – a long sought clinical strategy in these patients.

The current issue of Life Science Leader magazine can be found at www.lifescienceleader.com.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com